Ibrutinib (trade name: Imbruvica) is a small Bruton's tyrosine kinase (BTK) inhibitor. Ibrutinib is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia, a form of non-Hodgkin's lymphoma. Ibrutinib has been approved by the U.S Food and Drug Administration on November 19, 2013.
Product Name: Ibrutinib
CAS Number: 936563-96-1
Molecular Weight:  440.5036
Molecular Formula:  C25H24N6O2
Purity (HPLC): ≥99%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.